PROCEPT BioRobotics Appoints Former Shockwave Medical CFO Daniel Puckett to Board and Audit Committee
Summary
PROCEPT BioRobotics has expanded its board and appointed Daniel Puckett, former CFO of Shockwave Medical, as an independent director and member of the Audit Committee, enhancing financial and industry expertise.
Key Events
-
Board Expansion
The Board of Directors approved an increase in its size from eight to nine members.
-
New Independent Director Appointed
Mr. Daniel Puckett was appointed as a new Class III independent member of the Board, with his initial term expiring at the 2027 annual meeting.
-
Audit Committee Appointment
Mr. Puckett was also appointed as a member of the Audit Committee, effective immediately.
-
Experienced Financial Executive
Mr. Puckett previously served as Chief Financial Officer of Shockwave Medical, Inc. from April 2016 to February 2024, and held other senior finance roles at various companies, bringing significant medical device and financial expertise.
Analysis
PROCEPT BioRobotics has strengthened its corporate governance and financial oversight by appointing Daniel Puckett, a seasoned financial executive with extensive experience in the medical device industry, to its Board of Directors and Audit Committee. Mr. Puckett's background as the former CFO of Shockwave Medical, a leading medical device company, brings valuable strategic and financial expertise, which is particularly important following the company's recent financial reporting and strategic plan disclosures. This move signals a commitment to robust financial management and strategic guidance.
At the time of this filing, PRCT was trading at $25.35 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $19.35 to $66.85. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.